High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas

J Dermatol Sci. 2011 Dec;64(3):185-90. doi: 10.1016/j.jdermsci.2011.08.011. Epub 2011 Sep 8.


Background: Aberrant expression of microRNAs (miRNAs) has been implicated in oncogenesis of various tumors and primary cutaneous T cell lymphomas. Dicer, a ribonuclease III-like enzyme is essential for miRNA processing.

Objective: We initiated a retrospective study to characterize the alterations in the expression profile of Dicer in patients with primary cutaneous T cell lymphomas (CTCL).

Methods: A total of 50 consecutive patients with primary CTCL were studied, with the majority having mycosis fungoides (n=34). Five patients had primary cutaneous CD 30+ anaplastic large cell lymphoma, four patients each had lymphomatoid papulosis and primary cutaneous CD4-positive small/medium T-cell lymphoma, one primary cutaneous γδ T cell lymphoma, one Sézary syndrome and another subcutaneous panniculitis-like T cell lymphoma of αβ-phenotype. Immunohistochemistry was performed on paraffin sections using a commercially available antibody against Dicer. Intensity of expression was correlated with clinical parameters including disease specific survival (DSS) and time to progression (TTP).

Results: After a median follow-up of 74 months (range: 1-271), 12/50 patients (24%) have died. Univariate and multivariate analysis for disease-specific survival showed Dicer expression and stage as a negative predictive factor in the sole group of MF patients (n=34) as well as in the heterogeneous group of patients (n=50), but not gender, histological subtype, primary localization of disease, age and recurrence of lymphoma (p>0.05).

Conclusion: Our data suggest Dicer expression as a possible molecular marker in patients with MF and apparently indicate that miRNA(s) might be of clinical relevance in CTCL.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Austria
  • Biomarkers, Tumor / analysis*
  • DEAD-box RNA Helicases / analysis*
  • Disease Progression
  • Disease-Free Survival
  • Female
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Lymphoma, Primary Cutaneous Anaplastic Large Cell / enzymology
  • Lymphoma, T-Cell / enzymology
  • Lymphoma, T-Cell, Cutaneous / enzymology*
  • Lymphoma, T-Cell, Cutaneous / genetics
  • Lymphoma, T-Cell, Cutaneous / mortality
  • Lymphoma, T-Cell, Cutaneous / pathology
  • Lymphoma, T-Cell, Cutaneous / therapy
  • Lymphomatoid Papulosis / enzymology
  • Male
  • Middle Aged
  • Mycosis Fungoides / enzymology
  • Neoplasm Staging
  • Panniculitis / enzymology
  • Proportional Hazards Models
  • Retrospective Studies
  • Ribonuclease III / analysis*
  • Risk Assessment
  • Risk Factors
  • Sezary Syndrome / enzymology
  • Skin Neoplasms / enzymology*
  • Skin Neoplasms / genetics
  • Skin Neoplasms / mortality
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy
  • Survival Rate
  • Time Factors
  • Treatment Outcome
  • Up-Regulation


  • Biomarkers, Tumor
  • DICER1 protein, human
  • Ribonuclease III
  • DEAD-box RNA Helicases

Supplementary concepts

  • Subcutaneous panniculitis-like T-cell lymphoma